Invention Grant
- Patent Title: Compound that specifically binds to KIR3DL2 for use in the treatment of peripheral T cell lymphoma
-
Application No.: US16240906Application Date: 2019-01-07
-
Publication No.: US11078275B2Publication Date: 2021-08-03
- Inventor: Cecile Bonnafous , Helene Sicard , Renaud Buffet
- Applicant: INNATE PHARMA
- Applicant Address: FR Marseilles
- Assignee: INNATE PHARMA
- Current Assignee: INNATE PHARMA
- Current Assignee Address: FR Marseilles
- Agency: Saliwanchik, Lloyd & Eisenschenk
- Main IPC: C07K16/28
- IPC: C07K16/28 ; C07K16/30 ; G01N33/574 ; A61K39/00
Abstract:
The present invention relates to methods for the treatment, prevention and diagnosis of peripheral T cell lymphoma using compounds that specifically bind KIR3DL2. The invention also relates to use of antibodies that specifically bind KIR3DL2 in diagnostic and theranostic assays in the detection and treatment of peripheral T cell lymphoma.
Public/Granted literature
- US20190127463A1 COMPOUND THAT SPECIFICALLY BINDS TO KIR3DL2 FOR USE IN THE TREATMENT OF PERIPHERAL T CELL LYMPHOMA Public/Granted day:2019-05-02
Information query
